WFRF:(Koltowska Häggström Maria 1957 )
Search: WFRF:(Koltowska Häggström Maria 1957 ) > Long-Term Treatment...
- 3 of 14
- Previous record
- Next record
- To hitlist
Long-Term Treatment with Pegvisomant as Monotherapy in Patients with Acromegaly : Experience from Acrostudy
-
- Freda, Pamela U (author)
- Department of Medicine, Columbia University College of Physicians & Surgeons. New York, NY, USA
-
- Gordon, Murray B (author)
- Departments of Medicine and Neurosurgery, Allegheny Neuroendocrinology Center, Allegheny General Hospital Pittsburgh, PA, USA
-
- Kelepouris, Nicky (author)
- Pfizer, Collegeville, PA, USA
- show more...
- show less...
- Department of Medicine, Columbia University College of Physicians & Surgeons New York, NY, USA Departments of Medicine and Neurosurgery, Allegheny Neuroendocrinology Center, Allegheny General Hospital Pittsburgh, PA, USA (creator_code:org_t)
- 2015
- 2015
- English.
- In: Endocrine Practice. - 1530-891X .- 1934-2403. ; 21:3, s. 264-274
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Objective: To evaluate use of pegvisomant, a GH receptor antagonist, as monotherapy in ACROSTUDY, a global safety surveillance study set in 14 countries (373 sites).Methods: A descriptive analysis of safety, magnetic resonance imaging (MRI) reading and treatment outcomes in 710 subjects who received at least one pegvisomant dose as monotherapy during and up to 5 years follow-up in ACROSTUDY.Results: Subjects received 5.4 yr. (mean) of pegvisomant and were followed in ACROSTUDY 3.8 yr. (mean). A total of 1255 adverse events were reported in 345 subjects (48.6%). Serious adverse events were reported in 133 (18.7%) subjects including 22 deaths, none of which were attributed to pegvisomant use. Of 670 (94%) subjects with at least one liver function test reported in ACROSTUDY, 8 (1.2%) had reported increases in transaminases > 3X ULN. No liver failure was reported. Based on central MRI reading, 12 of 542 subjects (2.2%) had a confirmed increase or increase/decrease in tumor size. Injection-site reactions were reported in 2.3%. At 5 years of therapy, IGF-1 level was reported normal in 67.5% (mean dose 17.2 mg/day) and elevated in 29.9% (mean dose 19.8 mg/day). Subjects on 20 mg per day or more rose from 36% at 3 years to 41% at 5 years of therapy.Conclusions: ACROSTUDY data indicate that pegvisomant used as sole medical therapy is safe and effective medical treatment for acromegaly. The reported low incidence of pituitary tumor size increase and liver enzyme elevations are reassuring and support the positive benefit-risk of pegvisomant therapy.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- acromegaly
- pegvisomant
- ACROSTUDY
- clinical trial
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Endocrine Practice (Search for host publication in LIBRIS)
To the university's database
- 3 of 14
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Freda, Pamela U
- Gordon, Murray B
- Kelepouris, Nick ...
- Jonsson, Peter
- Koltowska-Häggst ...
- van der Lely, A ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Endocrinology an ...
- Articles in the publication
- Endocrine Practi ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
